Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Chen C-, Chen B-, Wang Y, Curman P, Beilinson HA, Brecht RM, et al. Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activity is required for V(D)J recombination. J Exp Med. 2021;218(8).

Kaeberlein M, Tyler JK. A new era for research into aging. Elife. 2021;10.

Gao J, Fu L, Lu X, Sukhanova M, Frankfurt O, Mohtashamian A, et al. Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of mutation and genetic complexity. Leuk Lymphoma. 2021:1-4.

Hao Y, Wu Y, Wang S, Wang C, Qu S, Li L, et al. Quantitative proteomics reveal the protective effects of EDS against osteoarthritis via attenuating inflammation and modulating immune response. J Ethnopharmacol. 2021;271:113780.

Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, et al. TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. medRxiv. 2021.

Sun D, Zhao Z, Spiegel S, Liu Y, Fan J, Amrollahi P, et al. Dye-free spectrophotometric measurement of nucleic acid-to-protein ratio for cell-selective extracellular vesicle discrimination. Biosens Bioelectron. 2021;179:113058.

Nakamichi K, Shen JZ, Lee CS, Lee A, Roberts EA, Simonson PD, et al. Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19. Sci Rep. 2021;11(1):4802.

Ghantous Y, Omar M, Broner EC, Agrawal N, Pearson AT, Rosenberg AJ, et al. A robust and interpretable gene signature for predicting the lymph node status of primary T1/T2 oral cavity squamous cell carcinoma. Int J Cancer. 2021.

Chapel DB, Lee EK, Da Silva AF, Teschan N, Feltmate C, Matulonis UA, et al. Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Mod Pathol. 2021;34(3):613-626.

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.